ENLIBRIUM
Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.
ENLIBRIUM
Industry:
Energy Health Care Medical
Founded:
2015-01-01
Address:
San Diego, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
15 M USD
Current Employees Featured
Founder
Investors List
TPG Biotech
TPG Biotech investment in Series A - Enlibrium
Avalon Ventures
Avalon Ventures investment in Series A - Enlibrium
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Enlibrium
Correlation Ventures
Correlation Ventures investment in Series A - Enlibrium